Muhammad Rashad*, Muhammad Athar Adil, Sohaib Peerzadah and Malik Saadullah
Many ideas have been drawn to employ plants therapeutically since the time of their ancient healing proclivity towards human health. The mythological profile of Achyranthes aspera reveals that it has been utilized to treat a variety of illnesses. In this study, Achyranthes aspera was standardized using a variety of in vitro analytical methods. Methanol was used to extract the dry powdered plant material, which was then treated with dichloromethane for liquid-liquid extraction. Furthermore, plant extracts (methanol and dichloromethane) were evaluated for antioxidant activity in vitro against the free radical DPPH. As connected with normal ascorbic acid, it was then measured for percent inhibition and inhibitory concentration (IC50). Maximum antioxidant efficacy was recorded with IC50 values 14.25 ± 0.013 μg /ml in methanol and 95.61 ± 0.015 μg/ml in dichloromethane extracts respectively. High performance liquid chromatography results showed 55.965% of quercetin which indicates the presence of flavonoid contents. The effective fractions (methanol and dichloromethane) were further investigated by in vitro α-amylase inhibitory activity for anti-diabetic potential and calculated in terms of percentage inhibition and IC50. Both extracts displayed substantial α-amylase inhibition activity, but the highest inhibition was observed with an IC50 21.58 ± 0.02 μg/ml in crude methanol extract. It is concluded that Achyranthes aspera can be used for isolation of novel compound which will be effective against diabetes mellitus (DM).
Published Date: 2022-08-26; Received Date: 2022-07-19
